Welcome to our dedicated page for Stevanato Group S.p.A. news (Ticker: STVN), a resource for investors and traders seeking the latest updates and insights on Stevanato Group S.p.A. stock.
Stevanato Group S.p.A., founded in 1949, is a leader in creating systems, processes, and services that ensure the integrity of parenteral medicines. The company operates through two main divisions:
- Pharmaceutical Systems (Ompi and Balda brands): Specializes in ready-to-use glass containers and bulk primary packaging such as syringes, cartridges, vials, and ampoules. Additionally, it provides high-quality, high-precision plastic solutions for diagnostic, pharmaceutical, and medical device applications.
- Engineering Systems (Spami, Optrel, Innoscan, and SVM brands): Focuses on glass forming technology, inspection systems, assembly, packaging machines, and serialization solutions for the pharmaceutical industry.
These divisions work in close synchronization, featuring daily exchanges that ensure the Stevanato Group maintains complete control over the entire production process, from sourcing the finest raw materials to providing exceptional after-sales customer service.
The group's commitment extends beyond manufacturing; through its SGLab, the Stevanato Group offers analytical and testing services that support pharmaceutical companies in ensuring the safety, efficacy, and integrity of their products.
Stevanato Group addresses customer needs across the entire drug life cycle, including development, clinical, and commercial stages, offering an integrated, end-to-end portfolio of products, processes, and services. The company operates in two segments: Biopharmaceutical and Diagnostic Solutions, which generates key revenue and encompasses products and services for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables; and Engineering.
Geographically, the company derives the majority of its revenue from Europe, the Middle East, and Africa, positioning itself as a significant player in the global pharmaceutical, biotechnology, and life sciences industries.
Stevanato Group S.p.A. (NYSE: STVN) has filed Amendment No. 1 (Form 20-F/A) to its 2021 Annual Report with the SEC to add the Interactive Data File and provide additional information. This was filed on
Shareholders can access the Form 20-F/A at www.stevanatogroup.com. A printed copy is available upon request.
Stevanato Group (NYSE: STVN) announced participation in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum, presenting virtually on March 22, 2022 at 9:00 a.m. EDT. A live audio webcast will be accessible on their website, with a replay available for 90 days post-event. The press release includes forward-looking statements regarding the company’s business strategies and recognizes the uncertainty in predicting future events. Founded in 1949, Stevanato Group specializes in drug containment and delivery solutions for the pharmaceutical and biotechnology sectors.
Stevanato Group (NYSE: STVN) has announced the acquisition of a new facility in Zhangjiagang, China, marking a strategic expansion phase. This 32,000 square meter facility will support the production of pre-sterilized EZ-fill® syringes and vials, meeting the growing demand in the biotech sector. Construction is set to begin in spring 2022, with production expected to start in 2023 and operational lines by early 2024. The expansion aims to streamline the drug development supply chain, with the potential to double current production capabilities by the end of 2024.
Stevanato Group (NYSE: STVN) reported a 12.5% increase in fourth quarter revenue to €232.6 million, with diluted EPS at €0.17 and adjusted EPS at €0.13. Full year revenue rose by 27.5% to €843.9 million. The company announced guidance for 2022, expecting revenue between €935 million to €945 million, with adjusted EPS projected at €0.49 to €0.51. Key drivers include strong performance in high-value solutions and demand for Covid-related products. The backlog also increased to €880 million, indicating robust future growth.
Stevanato Group (NYSE: STVN) has secured approximately
Stevanato Group (NYSE: STVN) announced it will release its financial results for Q4 and full year 2021 on March 8, 2022, at 6:30 a.m. ET. A conference call is scheduled for 8:30 a.m. ET on the same day, during which management will discuss the results and refer to a slide presentation available on their Investor Relations website. Participants can preregister or access the live call via provided links. An online archive of the call will be accessible after the live session until March 22, 2022.
Stevanato Group has appointed Riccardo Butta as President of the Americas, reinforcing its commitment to growth in the region. Butta brings over 30 years of management experience, including 20 years at Flex Ltd., where he oversaw the global commercial operations of Flex Health Solutions. This strategic move aims to enhance market penetration and customer proximity amid growing regional demand. CEO Franco Moro expressed confidence in Butta's capabilities to advance the company’s strategic priorities in this critical area.
Stevanato Group has extended its licensing agreement with Haselmeier for the Axis-D™ pen injector technology, broadening its offerings beyond diabetes to include obesity, cardiovascular disease, gastrointestinal disorders, pain management, and more. This strategic move enhances Stevanato's product portfolio and positions it to meet the increasing demand for drug delivery systems. The Alina® platform is designed for a variety of therapeutic regimens, ultimately benefiting patients and pharmaceutical companies during the drug development process.
Stevanato Group (NYSE: STVN) announced the construction of a new 6,750 square meter corporate headquarters in
Stevanato Group (NYSE: STVN) reported a 37% revenue increase to €214.5 million in Q3 2021, alongside a net profit of €18.6 million and diluted EPS of €0.07. Adjusted net profit rose 39% to €26.4 million, with adjusted diluted EPS at €0.10. The backlog also grew to €834 million. A discretionary bonus of €6.7 million affected net profits, but the company remains optimistic, raising its revenue guidance for the year and projecting adjusted diluted EPS between €0.45 and €0.47.
FAQ
What is the current stock price of Stevanato Group S.p.A. (STVN)?
What is the market cap of Stevanato Group S.p.A. (STVN)?
What does Stevanato Group S.p.A. specialize in?
What are the main divisions of Stevanato Group?
What brands fall under Stevanato's Pharmaceutical Systems division?
What services does the Engineering Systems division provide?
What is the role of SGLab in Stevanato Group?
Which industries does Stevanato Group serve?
From which regions does Stevanato Group derive most of its revenue?
How does Stevanato Group support the drug life cycle?
What kind of packaging solutions does Stevanato Group offer?
How long has Stevanato Group been in operation?
